Nyctea Technologies
Creates purification and administration of Biopharmaceuticals using electronically activated biomolecule control.
| EUR | 2021 | 2022 | 2023 |
|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 |
| % growth | - | (50 %) | - |
| EBITDA | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 |
| % profit margin | (2 %) | (588 %) | - |
| EV | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 |
Source: Company filings or news article, Dealroom estimates
Related Content
Nyctea Technologies is a pioneering startup focused on revolutionizing the production of biopharmaceuticals. Founded in 2020 by Gustav Ferrand Drake del Castillo and Professor Andreas Dahlin at Chalmers University of Technology, the company leverages cutting-edge research to develop a new technology platform aimed at enhancing the efficiency and cost-effectiveness of biopharmaceutical production.
The core innovation of Nyctea Technologies lies in its unique electronic control of biomolecules. This technology allows for the rapid and precise purification of biomolecules without the need for harmful buffers, which are chemicals typically used in the purification process. By electronically activating the capture and release of biomolecules, Nyctea Technologies offers a scalable solution that can significantly lower production costs and increase the speed of manufacturing biological pharmaceuticals.
Nyctea Technologies primarily serves clients in the biopharmaceutical industry, including pharmaceutical companies and research institutions. These clients are involved in the development and production of biological drugs, which are complex medicines made from living organisms. The market for biopharmaceuticals is growing rapidly, driven by the increasing demand for advanced medical treatments and therapies.
The business model of Nyctea Technologies is based on providing its innovative technology platform to biopharmaceutical companies. The company generates revenue through the sale of its purification devices and potentially through licensing agreements or partnerships with larger pharmaceutical firms. By improving the production and administration of biopharmaceuticals, Nyctea Technologies aims to accelerate the development of next-generation medical treatments.
In summary, Nyctea Technologies is at the forefront of biopharmaceutical innovation, offering a groundbreaking technology that enhances the production process, reduces costs, and speeds up the delivery of new medical treatments.
Keywords: biopharmaceuticals, biomolecule purification, electronic control, scalable solution, cost-effective, rapid production, medical treatments, pharmaceutical industry, innovative technology, Chalmers University.